208 related articles for article (PubMed ID: 29264751)
1. Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.
Underwood EA; Rochon PA; Moineddin R; Lee PE; Wu W; Pritchard KI; Tierney MC
Breast Cancer Res Treat; 2018 Apr; 168(2):299-310. PubMed ID: 29264751
[TBL] [Abstract][Full Text] [Related]
2. Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study.
Underwood EA; Jerzak KJ; Lebovic G; Rochon PA; Elser C; Pritchard KI; Tierney MC
Support Care Cancer; 2019 Aug; 27(8):3035-3043. PubMed ID: 30610433
[TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
[TBL] [Abstract][Full Text] [Related]
4. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J
Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
[TBL] [Abstract][Full Text] [Related]
6. Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls.
Palmer JL; Trotter T; Joy AA; Carlson LE
J Cancer Surviv; 2008 Dec; 2(4):275-82. PubMed ID: 18923905
[TBL] [Abstract][Full Text] [Related]
7. Decision-making impairments in breast cancer patients treated with tamoxifen.
Chen X; Li J; Chen J; Li D; Ye R; Zhang J; Zhu C; Tian Y; Wang K
Horm Behav; 2014 Jul; 66(2):449-56. PubMed ID: 25036869
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.
Jim HS; Phillips KM; Chait S; Faul LA; Popa MA; Lee YH; Hussin MG; Jacobsen PB; Small BJ
J Clin Oncol; 2012 Oct; 30(29):3578-87. PubMed ID: 22927526
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
12. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
Hermelink K; Henschel V; Untch M; Bauerfeind I; Lux MP; Munzel K
Cancer; 2008 Nov; 113(9):2431-9. PubMed ID: 18823033
[TBL] [Abstract][Full Text] [Related]
13. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review.
Bakoyiannis I; Tsigka EA; Perrea D; Pergialiotis V
Clin Drug Investig; 2016 Feb; 36(2):109-18. PubMed ID: 26619839
[TBL] [Abstract][Full Text] [Related]
15. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
Buwalda B; Schagen SB
Life Sci; 2013 Oct; 93(17):581-8. PubMed ID: 23353876
[TBL] [Abstract][Full Text] [Related]
16. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition?
Jenkins V; Atkins L; Fallowfield L
Eur J Cancer; 2007 Jun; 43(9):1342-7. PubMed ID: 17499988
[TBL] [Abstract][Full Text] [Related]
17. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments.
Vodermaier A
Womens Health (Lond); 2009 Sep; 5(5):503-16. PubMed ID: 19702450
[TBL] [Abstract][Full Text] [Related]
19. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
[TBL] [Abstract][Full Text] [Related]
20. Patterns of change in cognitive function with anastrozole therapy.
Bender CM; Merriman JD; Gentry AL; Ahrendt GM; Berga SL; Brufsky AM; Casillo FE; Dailey MM; Erickson KI; Kratofil FM; McAuliffe PF; Rosenzweig MQ; Ryan CM; Sereika SM
Cancer; 2015 Aug; 121(15):2627-36. PubMed ID: 25906766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]